| Mifamurtide |
| Muramyl tripeptide phosphatidylethanolamine; N-(N-Acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamid |
| (CAS 83461-56-7) |
 |
| Description： |
Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.
Target: Others
Mifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU.
|
| Product No. |
KT20039 |
| Product Name |
Mifamurtide |
| Synonyms |
Mepact; CGP-19835; MTP-PE; MTP-cephalin; CGP19835; L-MTP-PE; MLV19835 |
| Formal Name |
Muramyl tripeptide phosphatidylethanolamine; N-(N-Acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamid |
| CAS Number |
83461-56-7 |
| Molecular Formula |
C59H109N6O19P |
| Formula Weight |
1237.50 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
6-FITC
6-TAMRA
A-769662
AC-55541
Acarbose
Acetylcysteine
Adrafinil
AP1903
|
|
